Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05057013
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:28.715064+00:00
Published At
2025-08-11T00:00:00+00:00
Record Updated At
2025-08-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Bladder Cancer", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Cervical Cancer", "RAS Wild Type Colorectal Cancer", "Endometrial Cancer", "Gastric Cancer", "Hepatocellular Carcinoma (HCC)", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Oesophageal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Squamous Cell Cancer of the Head and Neck"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-08-11"
protocolSection.identificationModule.nctId
"NCT05057013"
protocolSection.identificationModule.officialTitle
"A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Castration-resistant Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • RAS Wild Type Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (HCC) (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
  • Oesophageal Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Squamous Cell Cancer of the Head and Neck (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.